This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
RocheHoldings Ltd. (RHHBY) recently expressed its disappointment at the Institutional Shareholder Services’ (ISS) recommendation that Illumina Inc.’s (ILMN - Snapshot Report) shareholders should not elect Roche’s independent director nominees to Illumina’s Board of Directors.
However, Roche said that it is pleased that ISS noted that Roche would make an excellent partner for Illumina, as the sequencing industry becomes more intertwined with the development of new drugs.
We note that last week Roche had issued a second letter to Illumina’s shareholders, requesting them to tender their shares to Roche for a payment of $51.00 a share. Roche’s second letter came after Illumina rejected Roche’s offer to acquire all its shares.
Since January, Roche has been trying to acquire Illumina, when it had first announced its bid to acquire all shares of Illumina at an offer price of $44.50 per share (aggregate value $5.7 billion) in cash. Then, on February 27, Roche extended the time-period for its bid to March 23 from February 24, 2012. In March, Roche further extended the time period for acquiring all outstanding shares of Illumina to April 20, 2012, from the previously announced date (March 23, 2012).
Additionally, in the last week of March, Roche increased its offer price for Illumina shares to $51.00 (aggregate value $6.7 billion) from $44.50 a share, while the other terms and conditions of the deal remained unchanged.
Roche believes that this acquisition will strengthen its position in the sequencing and microarrays market. Moreover, it will help address the growing demand for genetic/genomic solutions.
We currently have a Zacks #4 Rank (short-term Sell rating) on Roche.
Please login to Zacks.com or register to post a comment.